CHINOOK THERAPEUTICS INC's ticker is KDNY and the CUSIP is 16961L106. A total of 77 filers reported holding CHINOOK THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 2.12 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $13,811,221 | +64.9% | 359,480 | -0.7% | 0.03% | +55.6% |
| Q1 2023 | $8,376,549 | -11.6% | 361,838 | 0.0% | 0.02% | -14.3% |
| Q4 2022 | $9,480,156 | +103.6% | 361,838 | +52.7% | 0.02% | +75.0% |
| Q3 2022 | $4,657,000 | +43.1% | 236,905 | +27.3% | 0.01% | +50.0% |
| Q2 2022 | $3,255,000 | +6.9% | 186,097 | 0.0% | 0.01% | +33.3% |
| Q1 2022 | $3,045,000 | +0.3% | 186,097 | 0.0% | 0.01% | 0.0% |
| Q4 2021 | $3,036,000 | +130.9% | 186,097 | +80.6% | 0.01% | +100.0% |
| Q3 2021 | $1,315,000 | -9.7% | 103,068 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,456,000 | -9.1% | 103,068 | 0.0% | 0.00% | 0.0% |
| Q1 2021 | $1,601,000 | +45.3% | 103,068 | +48.3% | 0.00% | +50.0% |
| Q4 2020 | $1,102,000 | +30.4% | 69,488 | -80.0% | 0.00% | 0.0% |
| Q3 2020 | $845,000 | – | 347,440 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Samsara BioCapital, LLC | 5,161,888 | $135,241,466 | 29.11% |
| Octagon Capital Advisors LP | 2,551,703 | $66,854,619 | 10.41% |
| Affinity Asset Advisors, LLC | 818,035 | $21,432,517 | 8.40% |
| Frazier Life Sciences Management, L.P. | 4,345,559 | $113,853,646 | 7.08% |
| Saturn V Capital Management LP | 423,177 | $6,728,298 | 5.58% |
| Altium Capital Management LP | 385,000 | $10,087,000 | 5.13% |
| Deep Track Capital, LP | 3,000,000 | $78,600,000 | 3.30% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 340,389 | $8,914,788 | 2.75% |
| Vivo Capital, LLC | 872,151 | $22,850 | 2.63% |
| Nan Fung Group Holdings Ltd | 113,950 | $2,985,490 | 2.06% |